Ghani Karim, Boivin-Welch Michael, Roy Sylvie, Dakiw-Piaceski Angela, Barbier Martin, Pope Elena, Germain Lucie, Caruso Manuel
CHU de Québec-Université Laval Research Center (Oncology Division), Université Laval Cancer Research Center, and Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec, QC G1R 2J6, Canada.
CHU de Québec-Université Laval Research Center (Regenerative Medicine Division) and Centre de recherche en organogénèse expérimentale de l'Université Laval/LOEX, and Department of Surgery, Faculty of Medicine, Université Laval, Québec, QC, G1J 1Z4, Canada.
Mol Ther Methods Clin Dev. 2019 Jun 7;14:90-99. doi: 10.1016/j.omtm.2019.05.013. eCollection 2019 Sep 13.
The γ-retroviral vector is a gene delivery vehicle that is commonly used in gene therapy. Despite its efficacy, its strong enhancers contributed to malignant transformations in some hematopoietic stem cell (HSC) gene therapy trials. A safer version without viral enhancers (SIN) is available, but its production is cumbersome, as high titers can only be obtained in transient transfection. Our aim was to develop a system that could easily generate high-titer SIN vectors from stable producer cells. The use of the cytomegalovirus enhancer-promoter sequence to generate the full-length genomic RNA combined to sequences that decrease transcriptional readthrough (WPRE and strong polyadenylation sequences) led to 6 × 10 infectious units (IU)/mL of a SIN GFP vector in transient transfection. The incorporation of a blasticidin selection cassette to the retroviral plasmid allowed the generation of stable clones in the 293Vec packaging cells that release 2 × 10 IU/mL and 1.4 × 10 IU/mL of a SIN GFP and a SIN PIGA vector, respectively. A titer of 1.8 × 10 IU/mL was obtained with a SIN vector containing the long 8.9-kb COL7A1 cDNA. Thus, an efficient process was established for the generation of stable 293Vec-derived retrovirus producer cells that release high-titer SIN vectors.
γ-逆转录病毒载体是一种常用于基因治疗的基因递送工具。尽管其疗效显著,但其强大的增强子在一些造血干细胞(HSC)基因治疗试验中导致了恶性转化。有一种不含病毒增强子的更安全版本(自失活型,SIN),但其生产过程繁琐,因为只有通过瞬时转染才能获得高滴度。我们的目标是开发一种能够从稳定的生产细胞中轻松产生高滴度SIN载体的系统。使用巨细胞病毒增强子-启动子序列来产生全长基因组RNA,并结合减少转录通读的序列(土拨鼠肝炎病毒转录后调控元件,WPRE,和强聚腺苷酸化序列),在瞬时转染中产生了6×10感染单位(IU)/mL的SIN绿色荧光蛋白(GFP)载体。将杀稻瘟菌素选择盒整合到逆转录病毒质粒中,使得在293Vec包装细胞中产生稳定的克隆,分别释放2×10 IU/mL和1.4×10 IU/mL的SIN GFP载体和SIN磷酸肌醇聚糖A(PIGA)载体。对于一个含有8.9 kb长的Ⅶ型胶原基因(COL7A1)cDNA的SIN载体,获得了1.8×10 IU/mL的滴度。因此,建立了一个有效的方法来产生稳定的源自293Vec的逆转录病毒生产细胞,这些细胞可释放高滴度的SIN载体。